一项关于EIK1001联合帕博利珠单抗和化疗治疗4期非小细胞肺癌患者的安全性和有效性研究。 (TeLuRide-008)
一项EIK1001联合帕博利珠单抗和化疗治疗IV期非小细胞肺癌患者的全球、多中心、随机、双盲、安慰剂对照的2/3期研究(TeLuRide-008)。
This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.
研究概览
地位
详细说明
This is a global, multicenter, double-blind, placebo-controlled, randomized adaptive Phase 2/3 study to evaluate the clinical activity and safety of EIK1001 administered IV in combination with pembrolizumab and histologically appropriate chemotherapy (pemetrexed plus either carboplatin or cisplatin) to participants with Stage 4 non-squamous or (carboplatin plus either paclitaxel or nab-paclitaxel) for participants with squamous NSCLC who have not received prior systemic therapy. The study is conducted in 2 phases (Phase 2 and Phase 3) and analyzed in 3 parts (dose optimization, dose expansion and confirmatory hypothesis testing).
研究类型
注册 (估计的)
阶段
- 阶段2
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Elelta Shiferraw
- 电话号码:314-209-3659
- 邮箱:shiferrawe@eikontx.com
学习地点
-
-
Gauteng
-
Saxonwold、Gauteng、南非、2196
- 招聘中
- The Medical Oncology Centre of Rosebank
-
-
Western Cape
-
George、Western Cape、南非、6529
- 招聘中
- Task Eden
-
-
-
-
-
Linz、奥地利、4020
- 招聘中
- Kepler Universitaetsklinikum
-
-
-
-
-
Brasília、巴西、71635-580
- 招聘中
- Hospital Brasília Unidade Lago Sul
-
-
Ceará
-
Fortaleza、Ceará、巴西、60336-232
- 招聘中
- CRIO - Centro Regional Integrado de Oncologia
-
-
Espírito Santo
-
Cachoeiro de Itapemirim、Espírito Santo、巴西、29308-065
- 招聘中
- Hospital Evangélico de Cachoeiro de Itapemirim
-
-
Estado de Bahia
-
Salvador、Estado de Bahia、巴西、40170-110
- 招聘中
- Nucleo de Oncologia da Bahia
-
-
Rio Grande do Sul
-
Santa Maria、Rio Grande do Sul、巴西、97015-450
- 招聘中
- Clinica de Hematologia e Oncologia Viver Ltda
-
-
Rio de Janeiro
-
Rio de Janeiro、Rio de Janeiro、巴西、22250-905
- 招聘中
- Oncoclinicas Rio de Janeiro
-
-
-
-
-
Athens、希腊、11516
- 招聘中
- Henry Dunant Hospital Center
-
Thessaloniki、希腊、55535
- 招聘中
- 4th Department of Medical Oncology, European Interbalkan Medical Center
-
-
Central Macedonia
-
Thessaloniki、Central Macedonia、希腊、55535
- 招聘中
- Hospital Genesis
-
-
-
-
-
Hamburg、德国、22087
- 招聘中
- Katholische Marienkrankenhaus gGmbH
-
-
Saxony
-
Dresden、Saxony、德国、01307
- 招聘中
- University Hospital Carl Gustav Carus Dresden
-
-
-
-
-
Roma、意大利、00128
- 招聘中
- Policlinico Campus Bio-Medico
-
-
-
-
-
Brussels、比利时、1020
- 招聘中
- Centre Hospitalier Universitaire Brugmann
-
-
-
-
Lesser Poland Voivodeship
-
Krakow、Lesser Poland Voivodeship、波兰、31-864
- 招聘中
- GCPMED Sp. z o.o., Centrum Medyczne iMed24
-
-
-
-
New South Wales
-
Frenchs Forest、New South Wales、澳大利亚、2086
- 招聘中
- Cancer Care Northern Beaches
-
Waratah、New South Wales、澳大利亚、2298
- 招聘中
- Calvary Mater Newcastle Hospital
-
-
Victoria
-
Frankston、Victoria、澳大利亚、3199
- 招聘中
- Peninsula and Southeast Oncology (PASO) Medical
-
Saint Albans、Victoria、澳大利亚、3021
- 招聘中
- Sunshine Hospital - Western Health
-
-
-
-
Cluj
-
Cluj-Napoca、Cluj、罗马尼亚、400641
- 招聘中
- Medisprof Cancer Center
-
-
-
-
Alabama
-
Daphne、Alabama、美国、36526
- 招聘中
- Southern Cancer Center, P.C.
-
-
California
-
Glendale、California、美国、91204
- 招聘中
- Los Angeles Cancer Network
-
Orange、California、美国、92868
- 招聘中
- Providence St. Joseph Hospital
-
-
Colorado
-
Pueblo、Colorado、美国、81103
- 招聘中
- Rocky Mountain Cancer Centers, LLP
-
-
Florida
-
Doral、Florida、美国、33172
- 招聘中
- Omnicure Clinical Research
-
Plantation、Florida、美国、33322
- 招聘中
- Florida Clinical Trials Group
-
Tamarac、Florida、美国、33321
- 招聘中
- Florida Clinical Trials Group - Tamarac
-
-
Illinois
-
Peoria、Illinois、美国、61637
- 招聘中
- OSF Saint Francis Medical Center
-
-
New Mexico
-
Albuquerque、New Mexico、美国、87102
- 招聘中
- University of New Mexico - Comprehensive Cancer Center
-
-
New York
-
Mineola、New York、美国、11501
- 招聘中
- NYU Langone Hospital Long Island
-
New York、New York、美国、10016
- 招聘中
- NYU Langone Hospital Manhattan
-
The Bronx、New York、美国、10461
- 招聘中
- Jacobi Medical Center - Albert Einstein College of Medicine
-
White Plains、New York、美国、10601
- 招聘中
- White Plains Hospital
-
-
Tennessee
-
Nashville、Tennessee、美国、37203
- 招聘中
- Tennessee Oncology
-
-
Texas
-
Fort Worth、Texas、美国、76104
- 招聘中
- The Center for Cancer and Blood Disorders
-
-
Virginia
-
Blacksburg、Virginia、美国、24060
- 招聘中
- Blue Ridge Cancer Center
-
Fairfax、Virginia、美国、22031
- 招聘中
- Virginia Cancer Specialists, PC
-
Winchester、Virginia、美国、22601
- 招聘中
- Shenandoah Oncology P.C.
-
-
-
-
-
Barcelona、西班牙、08028
- 招聘中
- Instituto Oncologico Dr. Rosell (IOR)
-
Girona、西班牙、17007
- 招聘中
- Institut Catala D'Oncologia de Girona
-
Málaga、西班牙、29004
- 招聘中
- Hospital Quirónsalud Málaga
-
-
Cadiz
-
Jerez de la Frontera、Cadiz、西班牙、11407
- 招聘中
- Hospital Universitario de Jerez de la Frontera
-
-
Castellón
-
Castellon、Castellón、西班牙、12006
- 招聘中
- Consorci Hospitalari Provincial de Castello
-
-
Malaga
-
Málaga、Malaga、西班牙、29011
- 招聘中
- Hospital Regional Universitario de Malaga
-
-
-
-
Santa Fe Province
-
Rosario、Santa Fe Province、阿根廷、2000
- 招聘中
- Fundación de Estudios Clínicos
-
-
-
-
-
Seoul、韩国、03181
- 招聘中
- Kangbuk Samsung Medical Center (KBSMC)
-
-
Daegu
-
Daegu、Daegu、韩国、42415
- 招聘中
- Yeungnam University College of Medicine
-
-
Guro-gu
-
Seoul、Guro-gu、韩国、08308
- 招聘中
- Korea University Medical Center-Korea University Guro Hospital - Women's Cancer Center
-
-
Incheon Gwang'Yeogsi
-
Incheon、Incheon Gwang'Yeogsi、韩国、21565
- 招聘中
- Gachon University - Gil Medical Center
-
-
Jeollanam-do
-
Hwasun、Jeollanam-do、韩国、58128
- 招聘中
- Chonnam National University Hwasun Hospital (CNUHH)
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
-
Participant must be ≥ 18 years old at the time of signing the informed consent.
-
Participant has a life expectancy of at least 3 months.
-
Participant has histologically or cytologically confirmed Stage 4 NSCLC predominately squamous or non-squamous) and is considered a candidate for standard therapy with pembrolizumab and chemotherapy. Participants with NSCLC-NOS (not otherwise specified) will be considered as non-squamous NSCLC.
-
Participant must have documented evidence that mutation-directed therapy is not indicated, based on the absence of tumor-activating mutations or fusions (e.g., but not limited to EGFR, ALK, RET, ROS1, BRAF) for which approved first-line targeted therapies are available to the participant in their respective country.
-
Participant has at least 1 lesion with measurable disease at Baseline according to RECIST 1.1 as determined locally. Lesions situated in a previously irradiated area are considered measurable if progression has been shown in such lesions.
-
Participant has not received prior systemic therapy for advanced/metastatic NSCLC.
Note: Participants who received adjuvant or neoadjuvant treatment (after surgery and/or radiation therapy) and developed recurrent or metastatic disease more than 1 year after completing therapy are eligible.
-
Participant has an ECOG Performance Status of 0 to 1 assessed no more than 10 days before start of the treatment.
-
Participant has tumor tissue available for PD-L1 testing from a site that was not radiated prior to biopsy, and was obtained, ideally, after diagnosis of metastatic disease. Biopsies obtained prior to receipt of adjuvant/neoadjuvant chemotherapy will be permitted if recent biopsy is not feasible (provided the specimen is < 3yrs old).
Key Exclusion Criteria:
- has small cell elements present histologically and/or the tumors are not predominantly non-squamous or squamous NSCLC.
- is currently actively enrolled in or has recently participated in a study of an investigational agent and received investigational therapy within 4 weeks or 5 half-lives (whichever is longer) of administration of EIK1001 or placebo.
- has had major surgery (< 3 weeks prior to the first dose of study intervention administration).
- has received a live-virus vaccination within 30 days of the start of study intervention initiation.
- has received radiation therapy within 7 days of the first dose of study intervention administration.
- has completed palliative radiotherapy within 7 days of the first dose of study intervention administration.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:Arm 1 (Placebo in Combination with SOC)
Participants in this arm will receive EIK1001 Placebo + Standard of Care (SOC). |
Placebo control PD-1 inhibitor SOC Chemotherapy for squamous NSCLC SOC Chemotherapy for squamous NSCLC SOC Chemotherapy for non-squamous NSCLC |
|
实验性的:Arm 2 (EIK1001 in Combination with SOC)
Participants in this arm will receive EIK1001 (Selected Dose 1) + Standard of Care (SOC). |
PD-1 inhibitor SOC Chemotherapy for squamous NSCLC SOC Chemotherapy for squamous NSCLC SOC Chemotherapy for non-squamous NSCLC EIK1001 is a Toll like receptor 7/8 (TLR 7/8) dual agonist |
|
实验性的:Arm 3 (EIK1001 in Combination with SOC)
Participants in this arm will receive EIK1001 (Selected Dose 2) + Standard of Care (SOC). |
PD-1 inhibitor SOC Chemotherapy for squamous NSCLC SOC Chemotherapy for squamous NSCLC SOC Chemotherapy for non-squamous NSCLC EIK1001 is a Toll like receptor 7/8 (TLR 7/8) dual agonist |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression-free survival (PFS)
大体时间:Through study completion, up to 6 years
|
Progression-free survival (PFS) is defined as the time from the first dose of the study medication to the first documented disease progression according to RECIST 1.1 by BICR, or death due to any cause, whichever occurs first |
Through study completion, up to 6 years
|
|
Overall survival (OS)
大体时间:Through study completion, up to 10 years
|
OS defined as the time from the first dose of study medication to death due to any cause |
Through study completion, up to 10 years
|
|
Objective Response (OR)
大体时间:Through study completion, up to 6 years
|
Objective response (OR) is defined as participants who demonstrate complete response (CR) or partial response (PR) by RECIST 1.1 as assessed by the Investigator, adverse events (AEs), and discontinuation of study intervention due to an AE (Dose Optimization Only). |
Through study completion, up to 6 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Objective response (OR)
大体时间:Up to 6 years
|
Objective response (OR) is defined as participants who have a confirmed complete response (CR) or partial response (PR) according to RECIST 1.1 by BICR |
Up to 6 years
|
|
Duration of response (DOR)
大体时间:Up to 6 years
|
DOR is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first, in participants demonstrating CR or PR, according to RECIST 1.1 by BICR. |
Up to 6 years
|
|
Progression-free survival (PFS) by Investigator
大体时间:Up to 6 years
|
Progression-free survival (PFS) is defined as the time from the first dose of the study medication to the first documented disease progression according to RECIST 1.1 by Investigator, or death due to any cause, whichever occurs first. |
Up to 6 years
|
|
Overall Response Rate (ORR) by Investigator
大体时间:Up to 6 years
|
Objective Response as defined by participants who demonstrate confirmed CR or PR according to RECIST 1.1 by Investigator. |
Up to 6 years
|
|
Duration of Response (DOR) by Investigator
大体时间:Up to 6 years
|
DOR is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first, in participants demonstrating CR or PR, according to RECIST 1.1 by Investigator. |
Up to 6 years
|
|
Incidence of Adverse Events (AEs)
大体时间:Up to 2.5 years
|
Adverse Events (AEs) and discontinuation of study treatment due to any AE. |
Up to 2.5 years
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- EIK1001-008
- 2025-525013-23-00 (克蒂斯)
- KEYNOTE-G57 (其他标识符:Merck Sharp & Dohme LLC)
- MK-3475-G57 (其他标识符:Merck Sharp & Dohme LLC)
- 2025 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.